Home
/
Apellis Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Apellis Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Apellis Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$458.58M
Oct 30, 2025
Q2
2025
Jun 30, 2025
$178.49M
Jul 31, 2025
Q1
2025
Mar 31, 2025
$166.80M
May 7, 2025
Q3
2025
Sep 30, 2024
$196.83M
Oct 30, 2025
Q2
2025
Jun 30, 2024
$199.69M
Jul 31, 2025
Q1
2025
Mar 31, 2024
$172.33M
May 7, 2025
Q3
2024
Sep 30, 2023
$110.40M
Nov 5, 2024
Q2
2024
Jun 30, 2023
$94.97M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$44.85M
May 7, 2024
Q3
2023
Sep 30, 2022
$22.06M
Nov 1, 2023
Q2
2023
Jun 30, 2022
$16.32M
Jul 31, 2023
Q1
2023
Mar 31, 2022
$14.38M
May 4, 2023
Q3
2022
Sep 30, 2021
$5.65M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$623.0K
Aug 8, 2022
Q3
2021
Sep 30, 2020
$646.0K
Nov 8, 2021
Q2
2021
Jun 30, 2020
$0
Aug 9, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$215.72M
Oct 30, 2025
Q2
2025
Jun 30, 2025
($42.15M)
Jul 31, 2025
Q3
2025
Jun 30, 2025
($42.15M)
Oct 30, 2025
Q2
2025
Mar 31, 2025
($92.23M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($92.23M)
May 7, 2025
Q3
2025
Mar 31, 2025
($92.23M)
Oct 30, 2025
Q3
2025
Sep 30, 2024
($57.45M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($37.66M)
Jul 31, 2025
Q3
2025
Jun 30, 2024
($37.66M)
Oct 30, 2025
Q1
2025
Mar 31, 2024
($66.42M)
May 7, 2025
Q2
2025
Mar 31, 2024
($66.42M)
Jul 31, 2025
Q3
2025
Mar 31, 2024
($66.42M)
Oct 30, 2025
Q3
2024
Sep 30, 2023
($140.24M)
Nov 5, 2024
Q3
2024
Jun 30, 2023
($122.04M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($122.04M)
Aug 1, 2024
Q3
2024
Mar 31, 2023
($177.78M)
Nov 5, 2024
Q2
2024
Mar 31, 2023
($177.78M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($177.78M)
May 7, 2024
Q3
2023
Sep 30, 2022
($191.27M)
Nov 1, 2023
Q3
2023
Jun 30, 2022
($155.98M)
Nov 1, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$223.18M
Oct 30, 2025
Q2
2025
Jun 30, 2025
($33.29M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($83.33M)
May 7, 2025
Q3
2025
Sep 30, 2024
($47.28M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($29.44M)
Jul 31, 2025
Q1
2025
Mar 31, 2024
($62.09M)
May 7, 2025
Q3
2024
Sep 30, 2023
($137.08M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($120.44M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($175.08M)
May 7, 2024
Q3
2023
Sep 30, 2022
($152.94M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($148.62M)
Jul 31, 2023
Q1
2023
Mar 31, 2022
($129.00M)
May 4, 2023
Q3
2022
Sep 30, 2021
($128.00M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($194.29M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($124.59M)
May 4, 2022
Q3
2021
Sep 30, 2020
($129.55M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($115.51M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($98.79M)
Apr 28, 2021
Q3
2020
Sep 30, 2019
($69.95M)
Nov 2, 2020
Q2
2020
Jun 30, 2019
($63.48M)
Jul 30, 2020